Salicylic acid

Description

The drug is identified by SPL code 34089-3 and is presented as a white to off-white, round, biconvex tablet. The tablet is debossed with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. The formulation includes inactive ingredients such as lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for the topical treatment of acne. Patients are advised to first cleanse the affected area of the skin, select an appropriate size of the product, and apply it directly to the acne lesion. The product should be left in place for several hours before being removed and the area washed with warm water.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The product is intended for external use only. Healthcare professionals should ensure that the application site is clean and dry prior to administration. The recommended dosage and frequency of application should be determined based on the specific condition being treated, as well as the patient's response to therapy.

It is essential to apply the product evenly over the affected area, using a sufficient amount to cover the entire surface. The frequency of application may vary; however, it is generally advised to apply the product as directed by the prescribing information or as determined by the healthcare provider.

Patients should be instructed to wash their hands thoroughly after application to avoid unintentional contact with sensitive areas, such as the eyes or mucous membranes. In the event of accidental contact, the area should be rinsed immediately with water.

Healthcare professionals should monitor the patient for any adverse reactions or lack of efficacy, and adjust the treatment regimen as necessary.

Contraindications

The product is contraindicated for use on open wounds or skin exhibiting allergic reactions. Application in these conditions may exacerbate irritation or lead to adverse effects.

Warnings and Precautions

For external use only. It is imperative that healthcare professionals advise patients to avoid application on open wounds or areas of allergic skin to prevent adverse reactions.

In the event of sensitive irritation, the use of the product should be discontinued immediately. Patients should be instructed to store the product in a cool and dry place to maintain its efficacy and safety.

In cases of accidental ingestion, it is crucial to seek medical assistance or contact a Poison Control Center without delay to ensure appropriate management and care.

Side Effects

Patients should be aware that the product is intended for external use only. In the event of sensitive irritation, it is advised to discontinue use immediately and store the product in a cool and dry place.

Additionally, the product should not be applied to open wounds or areas of allergic skin, as this may exacerbate adverse reactions. These precautions are important to ensure the safety and well-being of patients using the product.

Drug Interactions

There are no specific drug interactions or laboratory test interactions identified in the available data. Therefore, no dosage adjustments or monitoring recommendations are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Syanti-Acnepatch. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

There is no specific pediatric use information available for this medication, including recommended ages, dosing differences, safety concerns, or special precautions for children. Healthcare professionals should exercise caution when considering the use of this medication in pediatric patients due to the absence of relevant data.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is no specific information regarding the use of SYANTI-ACNEPATCH during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this product to pregnant patients. Given the absence of established safety profiles, it is advisable to weigh the potential benefits against any unknown risks to fetal outcomes. Women of childbearing potential should be counseled accordingly.

Lactation

There is no specific information regarding the use of SYANTI-ACNEPATCH in lactating mothers or its effects on breastfed infants. Healthcare professionals should consider the lack of data when advising lactating mothers about the use of this product.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the context of overdosage, it is important to note that the available sections of the drug insert do not provide specific information regarding potential overdosage scenarios.

Healthcare professionals are advised to remain vigilant and consider the possibility of overdosage in patients, particularly in cases of suspected misuse or accidental ingestion. In the absence of detailed guidance, standard supportive care measures should be implemented.

Should an overdosage be suspected, it is recommended that healthcare providers monitor the patient closely for any adverse effects or symptoms that may arise. Symptomatic treatment should be initiated as necessary, and supportive measures should be tailored to the individual patient's needs.

In the event of an overdosage, it is prudent to consult local poison control centers or relevant medical authorities for further guidance on management strategies.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question.

Postmarketing Experience

No postmarketing experience details are available for SPL code 90375-7.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to emphasize the necessity of ensuring that the skin is clean prior to application. Patients should be instructed to avoid using the product on open wounds or areas of the skin that exhibit allergic reactions.

Providers should recommend that patients clean the skin with warm water to prepare the surface adequately. They should also guide patients in selecting an appropriately sized acne patch that can fully cover the acne. Patients should be informed that the acne patch should remain on the skin for the recommended duration. Once the application time has elapsed, patients can clean the skin again with warm water to remove any residue.

Storage and Handling

The product is available in various package configurations, with specific NDC numbers assigned for identification. Storage and handling instructions are not explicitly provided; therefore, standard practices for pharmaceutical products should be followed. It is advisable to store the product in a controlled environment, ensuring that it is kept at appropriate temperatures to maintain its integrity and efficacy. Containers should be kept sealed and protected from light and moisture to prevent degradation. Special handling requirements are not specified, but general precautions should be taken to ensure the product's quality is preserved throughout its shelf life.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Syanti-Acnepatch, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)